Stock Analysis on Net

Biogen Inc. (NASDAQ:BIIB)

This company has been moved to the archive! The financial data has not been updated since October 25, 2022.

Analysis of Long-term (Investment) Activity Ratios

Microsoft Excel

Long-term Activity Ratios (Summary)

Biogen Inc., long-term (investment) activity ratios

Microsoft Excel
Dec 31, 2021 Dec 31, 2020 Dec 31, 2019 Dec 31, 2018 Dec 31, 2017
Net fixed asset turnover 3.21 3.94 4.43 3.74 3.86
Net fixed asset turnover (including operating lease, right-of-use asset) 2.90 3.50 3.91 3.74 3.86
Total asset turnover 0.46 0.55 0.53 0.53 0.52
Equity turnover 1.01 1.26 1.08 1.03 0.97

Based on: 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31), 10-K (reporting date: 2019-12-31), 10-K (reporting date: 2018-12-31), 10-K (reporting date: 2017-12-31).

Long-term activity ratio Description The company
Net fixed asset turnover An activity ratio calculated as total revenue divided by net fixed assets. Biogen Inc. net fixed asset turnover ratio deteriorated from 2019 to 2020 and from 2020 to 2021.
Net fixed asset turnover (including operating lease, right-of-use asset) An activity ratio calculated as total revenue divided by net fixed assets (including operating lease, right-of-use asset). Biogen Inc. net fixed asset turnover ratio (with operating lease, right-of-use asset) deteriorated from 2019 to 2020 and from 2020 to 2021.
Total asset turnover An activity ratio calculated as total revenue divided by total assets. Biogen Inc. total asset turnover ratio improved from 2019 to 2020 but then deteriorated significantly from 2020 to 2021.
Equity turnover An activity ratio calculated as total revenue divided by shareholders’ equity. Biogen Inc. equity turnover ratio improved from 2019 to 2020 but then deteriorated significantly from 2020 to 2021.

Net Fixed Asset Turnover

Biogen Inc., net fixed asset turnover calculation, comparison to benchmarks

Microsoft Excel
Dec 31, 2021 Dec 31, 2020 Dec 31, 2019 Dec 31, 2018 Dec 31, 2017
Selected Financial Data (US$ in thousands)
Revenue 10,981,700 13,444,600 14,377,900 13,452,900 12,273,900
Property, plant and equipment, net 3,416,400 3,411,500 3,247,300 3,601,200 3,182,400
Long-term Activity Ratio
Net fixed asset turnover1 3.21 3.94 4.43 3.74 3.86
Benchmarks
Net Fixed Asset Turnover, Competitors2
AbbVie Inc. 11.00 8.73 11.23
Amgen Inc. 4.69 4.96 4.51
Bristol-Myers Squibb Co. 7.67 7.22 4.18
Danaher Corp. 7.77 6.83 7.78
Eli Lilly & Co. 3.15 2.83 2.83
Gilead Sciences Inc. 5.27 4.90 4.91
Johnson & Johnson 4.95 4.40 4.65
Merck & Co. Inc. 2.53 2.67 3.11
Moderna Inc. 14.24 0.67 0.00
Pfizer Inc. 5.46 3.01 3.71
Regeneron Pharmaceuticals Inc. 4.62 2.64 2.72
Thermo Fisher Scientific Inc. 4.71 5.45 5.38
Net Fixed Asset Turnover, Sector
Pharmaceuticals, Biotechnology & Life Sciences 5.06 4.27 4.30
Net Fixed Asset Turnover, Industry
Health Care 10.44 9.62 9.73

Based on: 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31), 10-K (reporting date: 2019-12-31), 10-K (reporting date: 2018-12-31), 10-K (reporting date: 2017-12-31).

1 2021 Calculation
Net fixed asset turnover = Revenue ÷ Property, plant and equipment, net
= 10,981,700 ÷ 3,416,400 = 3.21

2 Click competitor name to see calculations.

Long-term activity ratio Description The company
Net fixed asset turnover An activity ratio calculated as total revenue divided by net fixed assets. Biogen Inc. net fixed asset turnover ratio deteriorated from 2019 to 2020 and from 2020 to 2021.

Net Fixed Asset Turnover (including Operating Lease, Right-of-Use Asset)

Biogen Inc., net fixed asset turnover (including operating lease, right-of-use asset) calculation, comparison to benchmarks

Microsoft Excel
Dec 31, 2021 Dec 31, 2020 Dec 31, 2019 Dec 31, 2018 Dec 31, 2017
Selected Financial Data (US$ in thousands)
Revenue 10,981,700 13,444,600 14,377,900 13,452,900 12,273,900
 
Property, plant and equipment, net 3,416,400 3,411,500 3,247,300 3,601,200 3,182,400
Operating lease assets 375,400 433,300 427,000
Property, plant and equipment, net (including operating lease, right-of-use asset) 3,791,800 3,844,800 3,674,300 3,601,200 3,182,400
Long-term Activity Ratio
Net fixed asset turnover (including operating lease, right-of-use asset)1 2.90 3.50 3.91 3.74 3.86
Benchmarks
Net Fixed Asset Turnover (including Operating Lease, Right-of-Use Asset), Competitors2
AbbVie Inc. 9.57 7.46 10.06
Amgen Inc. 4.23 4.58 4.11
Bristol-Myers Squibb Co. 6.66 6.30 3.76
Danaher Corp. 6.10 5.30 5.84
Eli Lilly & Co. 2.93 2.63 2.66
Gilead Sciences Inc. 4.77 4.34 4.28
Johnson & Johnson 4.72 4.18 4.41
Merck & Co. Inc. 2.33 2.43 2.90
Moderna Inc. 12.78 0.52 0.00
Pfizer Inc. 4.59 2.74 3.39
Regeneron Pharmaceuticals Inc. 4.52 2.58 2.66
Thermo Fisher Scientific Inc. 3.98 4.82 4.69
Net Fixed Asset Turnover (including Operating Lease, Right-of-Use Asset), Sector
Pharmaceuticals, Biotechnology & Life Sciences 4.54 3.88 3.93
Net Fixed Asset Turnover (including Operating Lease, Right-of-Use Asset), Industry
Health Care 8.28 7.55 7.63

Based on: 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31), 10-K (reporting date: 2019-12-31), 10-K (reporting date: 2018-12-31), 10-K (reporting date: 2017-12-31).

1 2021 Calculation
Net fixed asset turnover (including operating lease, right-of-use asset) = Revenue ÷ Property, plant and equipment, net (including operating lease, right-of-use asset)
= 10,981,700 ÷ 3,791,800 = 2.90

2 Click competitor name to see calculations.

Long-term activity ratio Description The company
Net fixed asset turnover (including operating lease, right-of-use asset) An activity ratio calculated as total revenue divided by net fixed assets (including operating lease, right-of-use asset). Biogen Inc. net fixed asset turnover ratio (with operating lease, right-of-use asset) deteriorated from 2019 to 2020 and from 2020 to 2021.

Total Asset Turnover

Biogen Inc., total asset turnover calculation, comparison to benchmarks

Microsoft Excel
Dec 31, 2021 Dec 31, 2020 Dec 31, 2019 Dec 31, 2018 Dec 31, 2017
Selected Financial Data (US$ in thousands)
Revenue 10,981,700 13,444,600 14,377,900 13,452,900 12,273,900
Total assets 23,877,300 24,618,900 27,234,300 25,288,900 23,652,600
Long-term Activity Ratio
Total asset turnover1 0.46 0.55 0.53 0.53 0.52
Benchmarks
Total Asset Turnover, Competitors2
AbbVie Inc. 0.38 0.30 0.37
Amgen Inc. 0.40 0.39 0.37
Bristol-Myers Squibb Co. 0.42 0.36 0.20
Danaher Corp. 0.35 0.29 0.29
Eli Lilly & Co. 0.58 0.53 0.57
Gilead Sciences Inc. 0.40 0.36 0.36
Johnson & Johnson 0.52 0.47 0.52
Merck & Co. Inc. 0.46 0.52 0.55
Moderna Inc. 0.72 0.03 0.00
Pfizer Inc. 0.45 0.27 0.31
Regeneron Pharmaceuticals Inc. 0.63 0.50 0.53
Thermo Fisher Scientific Inc. 0.41 0.47 0.44
Total Asset Turnover, Sector
Pharmaceuticals, Biotechnology & Life Sciences 0.45 0.38 0.39
Total Asset Turnover, Industry
Health Care 0.76 0.70 0.71

Based on: 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31), 10-K (reporting date: 2019-12-31), 10-K (reporting date: 2018-12-31), 10-K (reporting date: 2017-12-31).

1 2021 Calculation
Total asset turnover = Revenue ÷ Total assets
= 10,981,700 ÷ 23,877,300 = 0.46

2 Click competitor name to see calculations.

Long-term activity ratio Description The company
Total asset turnover An activity ratio calculated as total revenue divided by total assets. Biogen Inc. total asset turnover ratio improved from 2019 to 2020 but then deteriorated significantly from 2020 to 2021.

Equity Turnover

Biogen Inc., equity turnover calculation, comparison to benchmarks

Microsoft Excel
Dec 31, 2021 Dec 31, 2020 Dec 31, 2019 Dec 31, 2018 Dec 31, 2017
Selected Financial Data (US$ in thousands)
Revenue 10,981,700 13,444,600 14,377,900 13,452,900 12,273,900
Total Biogen Inc. shareholders’ equity 10,896,200 10,700,300 13,343,200 13,039,600 12,612,800
Long-term Activity Ratio
Equity turnover1 1.01 1.26 1.08 1.03 0.97
Benchmarks
Equity Turnover, Competitors2
AbbVie Inc. 3.65 3.50
Amgen Inc. 3.63 2.58 2.30
Bristol-Myers Squibb Co. 1.29 1.12 0.51
Danaher Corp. 0.65 0.56 0.59
Eli Lilly & Co. 3.15 4.35 8.56
Gilead Sciences Inc. 1.28 1.34 0.98
Johnson & Johnson 1.27 1.31 1.38
Merck & Co. Inc. 1.28 1.90 1.81
Moderna Inc. 1.25 0.08 0.00
Pfizer Inc. 1.05 0.66 0.82
Regeneron Pharmaceuticals Inc. 0.86 0.77 0.71
Thermo Fisher Scientific Inc. 0.96 0.93 0.86
Equity Turnover, Sector
Pharmaceuticals, Biotechnology & Life Sciences 1.28 1.23 1.20
Equity Turnover, Industry
Health Care 2.10 2.07 2.07

Based on: 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31), 10-K (reporting date: 2019-12-31), 10-K (reporting date: 2018-12-31), 10-K (reporting date: 2017-12-31).

1 2021 Calculation
Equity turnover = Revenue ÷ Total Biogen Inc. shareholders’ equity
= 10,981,700 ÷ 10,896,200 = 1.01

2 Click competitor name to see calculations.

Long-term activity ratio Description The company
Equity turnover An activity ratio calculated as total revenue divided by shareholders’ equity. Biogen Inc. equity turnover ratio improved from 2019 to 2020 but then deteriorated significantly from 2020 to 2021.